Polymorphisms in DNA-Repair Genes in a Cohort of Prostate Cancer Patients from Different Areas in Spain: Heterogeneity between Populations as a Confounding Factor in Association Studies
Background Differences in the distribution of genotypes between individuals of the same ethnicity are an important confounder factor commonly undervalued in typical association studies conducted in radiogenomics. Objective To evaluate the genotypic distribution of SNPs in a wide set of Spanish prostate cancer patients for determine the homogeneity of the population and to disclose potential bias. Design, Setting, and Participants A total of 601 prostate cancer patients from Andalusia, Basque Country, Canary and Catalonia were genotyped for 10 SNPs located in 6 different genes associated to DNA repair: XRCC1 (rs25487, rs25489, rs1799782), ERCC2 (rs13181), ERCC1 (rs11615), LIG4 (rs1805388, rs1805386), ATM (rs17503908, rs1800057) and P53 (rs1042522). The SNP genotyping was made in a Biotrove OpenArray？ NT Cycler. Outcome Measurements and Statistical Analysis Comparisons of genotypic and allelic frequencies among populations, as well as haplotype analyses were determined using the web-based environment SNPator. Principal component analysis was made using the SnpMatrix and XSnpMatrix classes and methods implemented as an R package. Non-supervised hierarchical cluster of SNP was made using MultiExperiment Viewer. Results and Limitations We observed that genotype distribution of 4 out 10 SNPs was statistically different among the studied populations, showing the greatest differences between Andalusia and Catalonia. These observations were confirmed in cluster analysis, principal component analysis and in the differential distribution of haplotypes among the populations. Because tumor characteristics have not been taken into account, it is possible that some polymorphisms may influence tumor characteristics in the same way that it may pose a risk factor for other disease characteristics. Conclusion Differences in distribution of genotypes within different populations of the same ethnicity could be an important confounding factor responsible for the lack of validation of SNPs associated with radiation-induced toxicity, especially when extensive meta-analysis with subjects from different countries are carried out.
References
[1]
Guttmacher AE, Collins FS (2002) Genomic medicine–a primer. N Engl J Med 347: 1512–1520.
[2]
Bauchet M, McEvoy B, Pearson LN, Quillen EE, Sarkisian T, et al. (2007) Measuring European population stratification with microarray genotype data. Am J Hum Genet 80: 948–956.
[3]
Laayouni H, Calafell F, Bertranpetit J (2010) A genome-wide survey does not show the genetic distinctiveness of Basques. Hum Genet 127: 455–458.
[4]
Pino-Yanes M, Corrales A, Basaldua S, Hernandez A, Guerra L, et al. (2011) North African influences and potential bias in case-control association studies in the Spanish population. PLoS One 6: e18389.
[5]
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, et al. (2005) Cancer of the prostate. Crit Rev Oncol Hematol 56: 379–396.
[6]
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, et al. (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy>or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58: 25–33.
[7]
Johansson S, Svensson H, Denekamp J (2000) Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 48: 745–750.
[8]
Bentzen SM, Overgaard J (1994) Patient-to-Patient Variability in the Expression of Radiation-Induced Normal Tissue Injury. Semin Radiat Oncol 4: 68–80.
[9]
Henriquez-Hernandez LA, Bordon E, Pinar B, Lloret M, Rodriguez-Gallego C, et al. (2012) Prediction of normal tissue toxicity as part of the individualized treatment with radiotherapy in oncology patients. Surg Oncol 21: 201–206.
[10]
West CM, Barnett GC (2011) Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 3: 52.
[11]
West C, Rosenstein BS, Alsner J, Azria D, Barnett G, et al. (2010) Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 76: 1295–1296.
[12]
Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, et al. (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13: 65–77.
[13]
West CM, Dunning AM, Rosenstein BS (2012) Genome-wide association studies and prediction of normal tissue toxicity. Semin Radiat Oncol 22: 91–99.
[14]
Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, et al. (2011) Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol 98: 387–393.
[15]
Mangoni M, Bisanzi S, Carozzi F, Sani C, Biti G, et al. (2011) Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 81: 52–58.
[16]
Zhang L, Yang M, Bi N, Ji W, Wu C, et al. (2010) Association of TGF-beta1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy. Radiother Oncol 97: 19–25.
[17]
Biggerstaff M, Szymkowski DE, Wood RD (1993) Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J 12: 3685–3692.
[18]
Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, et al. (2006) Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12: 2545–2554.
[19]
Tanteles GA, Murray RJ, Mills J, Barwell J, Chakraborti P, et al. (2012) Variation in telangiectasia predisposing genes is associated with overall radiation toxicity. Int J Radiat Oncol Biol Phys 84: 1031–1036.
[20]
Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, et al. (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100: 1680–1686.
[21]
Morcillo-Suarez C, Alegre J, Sangros R, Gazave E, de Cid R, et al. (2008) SNP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 24: 1643–1644.
[22]
Clayton D (2012) snpStats: SnpMatrix and XSnpMatrix classes and methods. R package version 1.8.1.
[23]
Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
[24]
Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, et al. (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60: 1133–1139.
[25]
Andreassen CN, Alsner J (2009) Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 92: 299–309.
[26]
Buchholz TA (1999) Finding our sensitive patients. Int J Radiat Oncol Biol Phys 45: 547–548.
[27]
Clayton D (2001) Population Association. Handbook of statistical genetics: 519–540.
[28]
Sai K, Saito Y (2011) Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol 7: 967–988.
[29]
Rando JC, Cabrera VM, Larruga JM, Hernandez M, Gonzalez AM, et al. (1999) Phylogeographic patterns of mtDNA reflecting the colonization of the Canary Islands. Ann Hum Genet 63: 413–428.
[30]
Calafell F, Bertranpetit J (1994) Principal component analysis of gene frequencies and the origin of Basques. Am J Phys Anthropol 93: 201–215.
[31]
Fachal L, Gomez-Caamano A, Peleteiro P, Carballo A, Calvo-Crespo P, et al. (2012) Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiother Oncol 105: 321–328.
[32]
Wacholder S, Rothman N, Caporaso N (2000) Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 92: 1151–1158.
[33]
Reich DE, Goldstein DB (2001) Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol 20: 4–16.
[34]
Henriquez-Hernandez LA, Murias-Rosales A, Gonzalez-Hernandez A, de Leon AC, Diaz-Chico N, et al. (2010) Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol 34: 634–638.
[35]
Henriquez-Hernandez LA, Perez LF, Hernandez AG, de Leon AC, Diaz-Chico B, et al. (2010) TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy. Cancer Epidemiol 34: 490–493.
[36]
Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, et al. (2012) Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 105: 289–295.
